In various hematologic malignancies the receptor tyrosine kinase‐like orphan receptor 1 (ROR1) has been described to be overexpressed and targeting of ROR1 is a promising treatment option currently tested in clinical trials [24, 25, 26]. Here, ROR1 is linked to hematologic disorder.